Aripiprazole
lauroxil is a long acting injectable (LAI) pro-drug formulation
of aripiprazole approved in the U.S. for the treatment of
schizophrenia. Aripiprazole lauroxil is a dopamine D2
receptor partial antagonist, a 5-HT2A antagonist, and a 5-
HT1A partial agonist that was developed by Alkermes. It was Aripiprazole
lauroxil is a long acting injectable (LAI) pro-drug formulation
of aripiprazole approved in the U.S. for the treatment of
schizophrenia.28 Aripiprazole lauroxil is a dopamine D2
receptor partial antagonist, a 5-HT2A antagonist, and a 5-
HT1A partial agonist that was developed by Alkermes. It was
ChEBI: A dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripipraz
le, it is used for treatment of schizophrenia.
